Lipopolysaccharides from Akkermansia muciniphila

Description

• General description: Akkermansia muciniphila (A. muciniphila) is a Gram-negative, anaerobic, non-motile, non-spore-forming, and oval-shaped bacterium.[1] A. muciniphila inhabits the gastrointestinal tracts of more than 90% of adults and constitutes 1-4% of the fecal microbiota. A. muciniphila levels were suggested to serve as a biomarker for a healthy intestine.[2]
• Application: Lipopolysaccharides may have been used as a cell culture treatment: to impair barrier functions of Caco-2 cell monolayers tight junction[3]cocultured along with A. muciniphila to study its effects on the NLR family pyrin domain containing 3 (NLRP3) expressions in Raw264.7 cells to activate HepG2 cells as an endotoxin together with palmitic acid (PA)[4]
• Biochem/physiol Actions: LPS and its lipid A moiety stimulate cells of the innate immune system by the Toll-like receptor 4 (TLR4), a member of the Toll-like receptor protein family, which recognizes common pathogen-associated molecular patterns (PAMPs).[5],[6]A. muciniphila degrades mucus and utilizes it as a carbon/nitrogen source. Consequently, the host produces additional mucus while the bacterium produces oligosaccharides and Short Chain Fatty Acids (SCFAs) that can be utilized by the host and trigger the immune system. An additional protective effect of the SCFA is stimulation of mucus-associated microbiota growth, that serves as a barrier against penetration of pathogens to intestinal cells.[1],[7]A. muciniphila was crowned as the next-generation beneficial microbe. Several reports have indicated that A. muciniphila affects glucose metabolism, lipid metabolism, and intestinal immunity.[8] In addition, decreasing levels of A. muciniphila are related to the development of some diseases such as metabolic disorders and inflammatory diseases (obesity, type 2 diabetes, inflammatory bowel disease (IBD), autism and atopy.[9] Weir et al. found a correlation between low level of A. muciniphila and colorectal cancer.[10] Shigemetzu Y et al. found that A. muciniphila acts as a regulator of the response to PD-1 blockade which is used for anti-cancer immunotherapy. A. muciniphila induce dendritic cells to secrete IL-12, that is a critical component of the anti-cancer effect of PD-1 blockade.[11]LPSs from A. muciniphila stimulate NF-κB dependent secreted embryonic cell alkaline phosphatase (SEAP) production via TLR4. In addition, it induces IL-8, IL-6 and minimal amounts of IL-10 and TNF-α in peripheral blood mononuclear cells (PBMCs).[12] A. muciniphila stimulation of IL-8 production by enterocytes was shown to be significantly (100 fold) lower than E. coli stimulation. Low proinflammatory activity keep the mucosa-associated immune system alerted at an appropriate level for generation of mucosal homeostasis.[13]
• Other Notes: For additional information on our range of Biochemicals, please complete this form.